Recent chatter on X about Natera, Inc. (NTRA) has been buzzing with interest following the company's announcement of significant enrollment in its EXPAND clinical trial for a single gene noninvasive prenatal test. Many users on the platform have expressed enthusiasm for the potential impact of this development on the future of genetic testing. The milestone of surpassing 1,600 patients in the trial has sparked discussions about Natera's innovative edge in the medical research space.
Additionally, there has been notable attention on recent insider sales by top executives at Natera, with some on X raising questions about the timing and implications of these transactions. While a segment of the community remains optimistic about the stock's long-term prospects due to advancements like their AI platform for precision oncology, others are cautious, pointing to the stock's recent dip after a neutral rating from a major financial institution. This mix of developments keeps the conversation around NTRA dynamic and multifaceted.
Note: This discussion summary was generated from an AI condensation of post data.
Natera Congressional Stock Trading
Members of Congress have traded $NTRA stock 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $NTRA stock by members of Congress over the last 6 months:
- REPRESENTATIVE JOSH GOTTHEIMER has traded it 2 times. They made 1 purchase worth up to $15,000 on 08/22 and 1 sale worth up to $15,000 on 07/22.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
Natera Insider Trading Activity
Natera insiders have traded $NTRA stock on the open market 195 times in the past 6 months. Of those trades, 0 have been purchases and 195 have been sales.
Here’s a breakdown of recent trading of $NTRA stock by insiders over the last 6 months:
- MATTHEW RABINOWITZ (EXECUTIVE CHAIRMAN) has made 0 purchases and 14 sales selling 112,436 shares for an estimated $18,755,165.
- STEVEN LEONARD CHAPMAN (CEO AND PRESIDENT) has made 0 purchases and 26 sales selling 68,093 shares for an estimated $10,508,184.
- JONATHAN SHEENA has made 0 purchases and 73 sales selling 45,517 shares for an estimated $7,372,537.
- DANIEL RABINOWITZ (SEC. AND CHIEF LEGAL OFFICER) has made 0 purchases and 9 sales selling 26,193 shares for an estimated $4,330,531.
- SOLOMON MOSHKEVICH (PRESIDENT, CLINICALDIAGNOSTICS) has made 0 purchases and 29 sales selling 25,523 shares for an estimated $3,922,784.
- MICHAEL BURKES BROPHY (CHIEF FINANCIAL OFFICER) has made 0 purchases and 22 sales selling 18,161 shares for an estimated $2,679,046.
- GAIL BOXER MARCUS has made 0 purchases and 13 sales selling 14,795 shares for an estimated $2,316,079.
- JOHN FESKO (PRESIDENT, CHIEF BUS. OFFICER) has made 0 purchases and 8 sales selling 6,217 shares for an estimated $927,245.
- ROWAN E CHAPMAN sold 2,750 shares for an estimated $459,222
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Natera Hedge Fund Activity
We have seen 367 institutional investors add shares of Natera stock to their portfolio, and 255 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JPMORGAN CHASE & CO added 3,263,822 shares (+44.3%) to their portfolio in Q2 2025, for an estimated $551,390,088
- PRICE T ROWE ASSOCIATES INC /MD/ added 1,650,073 shares (+15.7%) to their portfolio in Q2 2025, for an estimated $278,763,332
- CITADEL ADVISORS LLC removed 1,301,513 shares (-61.3%) from their portfolio in Q2 2025, for an estimated $219,877,606
- KYNAM CAPITAL MANAGEMENT, LP removed 1,167,570 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $197,249,275
- CAPITAL WORLD INVESTORS added 1,013,229 shares (+255.6%) to their portfolio in Q2 2025, for an estimated $171,174,907
- LORD, ABBETT & CO. LLC removed 736,644 shares (-48.4%) from their portfolio in Q2 2025, for an estimated $124,448,637
- POINTSTATE CAPITAL LP removed 615,287 shares (-81.4%) from their portfolio in Q2 2025, for an estimated $103,946,585
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Natera Government Contracts
We have seen $296,845 of award payments to $NTRA over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- MODIFICATION TO EXTEND THE POP FOR SIX (6) MONTHS: $140,595
- GENETIC TESTING: $79,200
- TUMOR WHOLE EXOME SEQUENCING (WES) AND PERIPHERAL BLOOD CTDNA TEST TESTING (SINGLE ASSAY) SERVICES AND WES ...: $77,050
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
Natera Analyst Ratings
Wall Street analysts have issued reports on $NTRA in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Stephens & Co. issued a "Overweight" rating on 08/15/2025
- Piper Sandler issued a "Overweight" rating on 08/11/2025
- Barclays issued a "Overweight" rating on 08/08/2025
- RBC Capital issued a "Outperform" rating on 08/08/2025
- Evercore ISI Group issued a "Outperform" rating on 07/28/2025
- UBS issued a "Buy" rating on 05/09/2025
To track analyst ratings and price targets for Natera, check out Quiver Quantitative's $NTRA forecast page.
Natera Price Targets
Multiple analysts have issued price targets for $NTRA recently. We have seen 7 analysts offer price targets for $NTRA in the last 6 months, with a median target of $210.0.
Here are some recent targets:
- Brandon Couillard from Wells Fargo set a target price of $175.0 on 09/22/2025
- Mason Carrico from Stephens & Co. set a target price of $183.0 on 08/15/2025
- David Westenberg from Piper Sandler set a target price of $220.0 on 08/11/2025
- Conor McNamara from RBC Capital set a target price of $255.0 on 08/08/2025
- Luke Sergott from Barclays set a target price of $210.0 on 08/08/2025
- Daniel Markowitz from Evercore ISI Group set a target price of $170.0 on 07/28/2025
- Elizabeth Garcia from UBS set a target price of $218.0 on 05/09/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
